51.11 USD
-0.06 (-0.12%)
51.11 USD
0 (0%)
Taking everything into account, SUPN scores 5 out of 10 in our fundamental rating. SUPN was compared to 190 industry peers in the Pharmaceuticals industry. SUPN has only an average score on both its financial health and profitability. SUPN is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year SUPN was profitable.
SUPN had a positive operating cash flow in the past year.
Each year in the past 5 years SUPN has been profitable.
Each year in the past 5 years SUPN had a positive operating cash flow.
1.2 Ratios
SUPN's Return On Assets of -1.35% is fine compared to the rest of the industry. SUPN outperforms 75.52% of its industry peers.
SUPN has a Return On Equity of -1.82%. This is in the better half of the industry: SUPN outperforms 77.60% of its industry peers.
The Return On Invested Capital of SUPN (2.34%) is better than 79.69% of its industry peers.
The Average Return On Invested Capital over the past 3 years for SUPN is significantly below the industry average of 12.84%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.35% | ||
| ROE | -1.82% | ||
| ROIC | 2.34% |
ROA(3y)3.02%
ROA(5y)4.13%
ROE(3y)4.71%
ROE(5y)7.54%
ROIC(3y)2.7%
ROIC(5y)4.37%
1.3 Margins
SUPN's Profit Margin has declined in the last couple of years.
The Operating Margin of SUPN (6.08%) is better than 79.69% of its industry peers.
In the last couple of years the Operating Margin of SUPN has declined.
SUPN's Gross Margin of 89.91% is amongst the best of the industry. SUPN outperforms 92.19% of its industry peers.
In the last couple of years the Gross Margin of SUPN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.08% | ||
| PM (TTM) | N/A | ||
| GM | 89.91% |
OM growth 3Y-9.85%
OM growth 5Y-18.4%
PM growth 3Y6.61%
PM growth 5Y-17.27%
GM growth 3Y0.96%
GM growth 5Y-1.32%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), SUPN is destroying value.
SUPN has more shares outstanding than it did 1 year ago.
SUPN has more shares outstanding than it did 5 years ago.
SUPN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
SUPN has an Altman-Z score of 6.06. This indicates that SUPN is financially healthy and has little risk of bankruptcy at the moment.
SUPN's Altman-Z score of 6.06 is fine compared to the rest of the industry. SUPN outperforms 76.56% of its industry peers.
SUPN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 6.06 |
ROIC/WACC0.25
WACC9.45%
2.3 Liquidity
A Current Ratio of 1.80 indicates that SUPN should not have too much problems paying its short term obligations.
With a Current ratio value of 1.80, SUPN is not doing good in the industry: 65.63% of the companies in the same industry are doing better.
SUPN has a Quick Ratio of 1.56. This is a normal value and indicates that SUPN is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.56, SUPN is doing worse than 60.94% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.8 | ||
| Quick Ratio | 1.56 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 0.32% over the past year.
The Earnings Per Share has been growing slightly by 6.93% on average over the past years.
The Revenue has been growing slightly by 4.54% in the past year.
The Revenue has been growing by 11.00% on average over the past years. This is quite good.
EPS 1Y (TTM)0.32%
EPS 3Y44.39%
EPS 5Y6.93%
EPS Q2Q%-13.68%
Revenue 1Y (TTM)4.54%
Revenue growth 3Y4.51%
Revenue growth 5Y11%
Sales Q2Q%9.34%
3.2 Future
SUPN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.52% yearly.
SUPN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.93% yearly.
EPS Next Y-3.99%
EPS Next 2Y21.18%
EPS Next 3Y17.74%
EPS Next 5Y19.52%
Revenue Next Year9.32%
Revenue Next 2Y16.13%
Revenue Next 3Y15.75%
Revenue Next 5Y14.93%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 16.49, SUPN is valued correctly.
84.38% of the companies in the same industry are more expensive than SUPN, based on the Price/Earnings ratio.
SUPN's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.19.
The Price/Forward Earnings ratio is 11.80, which indicates a very decent valuation of SUPN.
Compared to the rest of the industry, the Price/Forward Earnings ratio of SUPN indicates a rather cheap valuation: SUPN is cheaper than 86.46% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.92, SUPN is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.49 | ||
| Fwd PE | 11.8 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, SUPN is valued cheaply inside the industry as 80.21% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, SUPN is valued a bit cheaper than 79.17% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 41.42 | ||
| EV/EBITDA | 19.86 |
4.3 Compensation for Growth
A more expensive valuation may be justified as SUPN's earnings are expected to grow with 17.74% in the coming years.
PEG (NY)N/A
PEG (5Y)2.38
EPS Next 2Y21.18%
EPS Next 3Y17.74%
5. Dividend
5.1 Amount
No dividends for SUPN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
51.11
-0.06 (-0.12%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners104.2%
Inst Owner Change0%
Ins Owners4.26%
Ins Owner Change2.8%
Market Cap2.93B
Revenue(TTM)681.54M
Net Income(TTM)-19.12M
Analysts83.33
Price Target62.56 (22.4%)
Short Float %8.77%
Short Ratio5.61
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)77.78%
Min EPS beat(2)67.83%
Max EPS beat(2)87.73%
EPS beat(4)4
Avg EPS beat(4)62.07%
Min EPS beat(4)15.55%
Max EPS beat(4)87.73%
EPS beat(8)7
Avg EPS beat(8)65.74%
EPS beat(12)9
Avg EPS beat(12)51.6%
EPS beat(16)10
Avg EPS beat(16)29.18%
Revenue beat(2)2
Avg Revenue beat(2)5.28%
Min Revenue beat(2)5.28%
Max Revenue beat(2)5.29%
Revenue beat(4)3
Avg Revenue beat(4)4.96%
Min Revenue beat(4)-0.71%
Max Revenue beat(4)9.98%
Revenue beat(8)6
Avg Revenue beat(8)5.09%
Revenue beat(12)8
Avg Revenue beat(12)3.15%
Revenue beat(16)11
Avg Revenue beat(16)2.6%
PT rev (1m)1.38%
PT rev (3m)40.03%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-56.74%
EPS NY rev (1m)0%
EPS NY rev (3m)24.89%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.53%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.51%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.49 | ||
| Fwd PE | 11.8 | ||
| P/S | 4.3 | ||
| P/FCF | 41.42 | ||
| P/OCF | 40.77 | ||
| P/B | 2.79 | ||
| P/tB | 9.54 | ||
| EV/EBITDA | 19.86 |
EPS(TTM)3.1
EY6.07%
EPS(NY)4.33
Fwd EY8.48%
FCF(TTM)1.23
FCFY2.41%
OCF(TTM)1.25
OCFY2.45%
SpS11.89
BVpS18.31
TBVpS5.36
PEG (NY)N/A
PEG (5Y)2.38
Graham Number35.73
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.35% | ||
| ROE | -1.82% | ||
| ROCE | 3.81% | ||
| ROIC | 2.34% | ||
| ROICexc | 3.16% | ||
| ROICexgc | 38.99% | ||
| OM | 6.08% | ||
| PM (TTM) | N/A | ||
| GM | 89.91% | ||
| FCFM | 10.38% |
ROA(3y)3.02%
ROA(5y)4.13%
ROE(3y)4.71%
ROE(5y)7.54%
ROIC(3y)2.7%
ROIC(5y)4.37%
ROICexc(3y)4.39%
ROICexc(5y)6.6%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)4.82%
ROCE(5y)7.36%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y11.61%
ROICexc growth 5Y-8.56%
OM growth 3Y-9.85%
OM growth 5Y-18.4%
PM growth 3Y6.61%
PM growth 5Y-17.27%
GM growth 3Y0.96%
GM growth 5Y-1.32%
F-Score4
Asset Turnover0.48
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 1.32% | ||
| Cap/Sales | 0.16% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 56.66% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.8 | ||
| Quick Ratio | 1.56 | ||
| Altman-Z | 6.06 |
F-Score4
WACC9.45%
ROIC/WACC0.25
Cap/Depr(3y)0.67%
Cap/Depr(5y)5.39%
Cap/Sales(3y)0.09%
Cap/Sales(5y)0.25%
Profit Quality(3y)2940.94%
Profit Quality(5y)1832.68%
High Growth Momentum
Growth
EPS 1Y (TTM)0.32%
EPS 3Y44.39%
EPS 5Y6.93%
EPS Q2Q%-13.68%
EPS Next Y-3.99%
EPS Next 2Y21.18%
EPS Next 3Y17.74%
EPS Next 5Y19.52%
Revenue 1Y (TTM)4.54%
Revenue growth 3Y4.51%
Revenue growth 5Y11%
Sales Q2Q%9.34%
Revenue Next Year9.32%
Revenue Next 2Y16.13%
Revenue Next 3Y15.75%
Revenue Next 5Y14.93%
EBIT growth 1Y-47.81%
EBIT growth 3Y-5.79%
EBIT growth 5Y-9.43%
EBIT Next Year10.08%
EBIT Next 3Y40.06%
EBIT Next 5Y32.85%
FCF growth 1Y-23.92%
FCF growth 3Y11.03%
FCF growth 5Y4.05%
OCF growth 1Y-23.21%
OCF growth 3Y10.6%
OCF growth 5Y3.74%
SUPERNUS PHARMACEUTICALS INC / SUPN FAQ
Can you provide the ChartMill fundamental rating for SUPERNUS PHARMACEUTICALS INC?
ChartMill assigns a fundamental rating of 5 / 10 to SUPN.
What is the valuation status for SUPN stock?
ChartMill assigns a valuation rating of 6 / 10 to SUPERNUS PHARMACEUTICALS INC (SUPN). This can be considered as Fairly Valued.
What is the profitability of SUPN stock?
SUPERNUS PHARMACEUTICALS INC (SUPN) has a profitability rating of 5 / 10.
Can you provide the expected EPS growth for SUPN stock?
The Earnings per Share (EPS) of SUPERNUS PHARMACEUTICALS INC (SUPN) is expected to decline by -3.99% in the next year.